,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2012-08-07 02:21:00,Warner Chilcott 's ( WCRX ) second-quarter 2012 earnings (excluding special items) of $1.03 per share handsomely beat the Zacks Consensus Estimate of 80 cents and the year-ago earnings of 94 cents.,0.9480392932891846,0.030342528596520424,0.021618230268359184,positive,0.9176967740058899
1,2012-08-07 02:21:00,"Lower selling, general & administrative costs boosted earnings in the reported quarter.",0.9461169838905334,0.026632115244865417,0.027250895276665688,positive,0.9194848537445068
2,2012-08-07 02:21:00,Revenues in the reported quarter declined 4.8% to $638 million.,0.017328938469290733,0.9738019108772278,0.008869162760674953,negative,-0.9564729928970337
3,2012-08-07 02:21:00,"The decline was primarily attributable to lower sales of osteoporosis drug, Actonel -- acquired from Procter & Gamble Co. ( PG ) in 2009 -- due to generic competition.",0.020132672041654587,0.9645546078681946,0.01531278807669878,negative,-0.9444219470024109
4,2012-08-07 02:21:00,"Moreover, reduced sales of dermatological product Doryx hurt revenues in the reported quarter.",0.01844133995473385,0.9725828766822815,0.008975798264145851,negative,-0.9541415572166443
5,2012-08-07 02:21:00,"Revenues, however, beat the Zacks Consensus Estimate of $610 million.",0.9079048037528992,0.05959537252783775,0.032499801367521286,positive,0.8483094573020935
6,2012-08-07 02:21:00,Revenues from osteoporosis products declined 17.4% to $166 million.,0.017296433448791504,0.9731031060218811,0.009600477293133736,negative,-0.9558066725730896
7,2012-08-07 02:21:00,Actonel sales declined 22.3% to $150 million.,0.017808137461543083,0.9720432758331299,0.010148589499294758,negative,-0.9542351365089417
8,2012-08-07 02:21:00,The loss of patent exclusivity of the drug in Western Europe in December 2010 hurt revenues in the quarter.,0.017918016761541367,0.9723953604698181,0.009686625562608242,negative,-0.9544773697853088
9,2012-08-07 02:21:00,Bulk of the revenues (60%) came from the US.,0.0139742661267519,0.00982338935136795,0.9762023091316223,neutral,0.004150876775383949
10,2012-08-07 02:21:00,US sales of the drug were down 15% in the second quarter of 2012 due to a 37% decrease in filled prescriptions.,0.01702990010380745,0.9725946187973022,0.010375464335083961,negative,-0.9555647373199463
11,2012-08-07 02:21:00,"Warner Chilcott, which expects Actonel sales to continue declining, believes that osteoporosis therapy Atelvia (launched in December 2010) will help counter the loss of revenues from Actonel in the US.",0.24853423237800598,0.6944409608840942,0.05702482908964157,negative,-0.44590672850608826
12,2012-08-07 02:21:00,"Atelvia contributed $16 million to total revenues in the second quarter of 2012, flat sequentially.",0.08054950088262558,0.018147669732570648,0.9013028740882874,neutral,0.06240183115005493
13,2012-08-07 02:21:00,Revenues from oral contraceptives climbed 17.4% to $135 million.,0.9518589377403259,0.02023020200431347,0.02791091799736023,positive,0.9316287636756897
14,2012-08-07 02:21:00,A 209% jump in the sales of Lo Loestrin FE (launched in the US in 2011) to $34 million more than mitigated the 9% decline in the sales of Loestrin 24 FE.,0.9422879219055176,0.04072025790810585,0.01699184626340866,positive,0.9015676379203796
15,2012-08-07 02:21:00,Sales of Loestrin 24 FE declined due to lower filled prescriptions coupled with an increase in sales-related deductions.,0.018861042335629463,0.9697876572608948,0.011351240798830986,negative,-0.9509266018867493
16,2012-08-07 02:21:00,"Sales of hormone therapy products climbed 34.7% to $53 million in the second quarter of 2012, driven by increased sales of Estrace cream (up 21.1% to $46 million).",0.9558799862861633,0.0207376591861248,0.02338237874209881,positive,0.9351423382759094
17,2012-08-07 02:21:00,A 15% increase in filled prescriptions in addition to higher average selling prices led to the rise in Estrace cream sales in the reported quarter.,0.9496402144432068,0.019586646929383278,0.030773155391216278,positive,0.9300535917282104
18,2012-08-07 02:21:00,Sales of dermatological product Doryx declined 28.1% to $23 million.,0.01754196174442768,0.9735302329063416,0.00892777182161808,negative,-0.9559882879257202
19,2012-08-07 02:21:00,Generic competition and an increase in sales-related deductions hurt sales of the drug during the reported quarter.,0.01866462267935276,0.9699244499206543,0.011410924606025219,negative,-0.9512598514556885
20,2012-08-07 02:21:00,We remind investors that Warner Chilcott suffered a huge blow regarding the 150 mg dosage of Doryx in April 2012.,0.03998640552163124,0.9355044960975647,0.02450907602906227,negative,-0.8955180644989014
21,2012-08-07 02:21:00,"On April 30, 2012, a US district court issued a verdict regarding Mylan ( MYL ) and Impax Laboratories ' ( IPXL ) applications to the FDA to sell their generic versions of the drug.",0.26403361558914185,0.4755525290966034,0.26041379570961,negative,-0.21151891350746155
22,2012-08-07 02:21:00,The court ruled the generic versions of neither of the companies infringed the patent of Doryx.,0.06841858476400375,0.6654325127601624,0.2661488652229309,negative,-0.5970139503479004
23,2012-08-07 02:21:00,"Following the verdict, Mylan entered the US market with its generic version of Doryx 150 mg in May 2012.",0.30626779794692993,0.006723297294229269,0.6870089173316956,neutral,0.2995445132255554
24,2012-08-07 02:21:00,"Sales of gastroenterology product Asacol and urology product Enablex were more or less flat at $187 million and $41 million, respectively.",0.016670985147356987,0.9656251668930054,0.017703793942928314,negative,-0.948954164981842
25,2012-08-07 02:21:00,"Selling, general and administrative (SG&A) expenses declined 30% in the reported quarter to $173 million.",0.0172593854367733,0.9738751649856567,0.008865424431860447,negative,-0.9566158056259155
26,2012-08-07 02:21:00,"All the components of SG&A expenses- advertising and promotion costs, selling and distribution expenses and general, administrative and other- declined in the reported quarter.",0.015910444781184196,0.9679968953132629,0.01609264500439167,negative,-0.9520864486694336
27,2012-08-07 02:21:00,Research and development (R&D) costs declined 8% to $23 million in the second quarter of 2012.,0.01916414685547352,0.9707366228103638,0.010099176317453384,negative,-0.9515724778175354
28,2012-08-07 02:21:00,"Apart from announcing second quarter results, Warner Chilcott upped its 2012 adjusted earnings guidance.",0.8345606327056885,0.04184091463685036,0.12359848618507385,positive,0.7927197217941284
29,2012-08-07 02:21:00,Warner Chilcott now expects adjusted earnings in the range of $3.55-$3.65 (previous guidance: $3.30-$3.40).,0.0916009172797203,0.007196349557489157,0.9012027382850647,neutral,0.08440456539392471
30,2012-08-07 02:21:00,The Zacks Consensus Estimate of $3.61 per share is well within the company's new guidance range.,0.7128415107727051,0.019624726846814156,0.26753368973731995,positive,0.6932168006896973
31,2012-08-07 02:21:00,Warner Chilcott trimmed its SG&A guidance to $775-$825 million (previous guidance: $800-$850 million).,0.04195442423224449,0.820980966091156,0.1370646059513092,negative,-0.7790265679359436
32,2012-08-07 02:21:00,"Cost savings due to the restructuring of Warner Chilcott's operations in Western European nations such as Belgium, the Netherlands, France, Germany, Italy, Spain, Switzerland and the UK contributed to the reduced guidance.",0.021442053839564323,0.9633426666259766,0.01521528884768486,negative,-0.9419006109237671
33,2012-08-07 02:21:00,R&D expenses are now projected in the range of $100-$120 million (previous guidance: $110-$130 million).,0.01832544058561325,0.0170473400503397,0.9646272659301758,neutral,0.001278100535273552
34,2012-08-07 02:21:00,Warner Chilcott continues to expect revenues in the range of $2.4 billion and $2.5 billion.,0.1999993771314621,0.00678326515480876,0.7932173013687134,neutral,0.19321611523628235
35,2012-08-07 02:21:00,The Zacks Consensus Estimate is $2.48 billion.,0.017183806747198105,0.008223187178373337,0.9745930433273315,neutral,0.008960619568824768
36,2012-08-07 02:21:00,We currently have a Neutral recommendation on Warner Chilcott in the long run.,0.025588184595108032,0.13572457432746887,0.8386873006820679,neutral,-0.11013638973236084
37,2012-08-07 02:21:00,The stock carries a Zacks #3 Rank (Hold rating) in the short run.,0.2663762867450714,0.012906438671052456,0.7207172513008118,neutral,0.253469854593277
38,2012-08-07 02:21:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
39,2012-08-07 02:21:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204561054706573,0.01563790813088417,0.9741575717926025,neutral,-0.005433347076177597
